Navigation Links
Debate over safety of gene therapy trials focuses on issue of informed consent
Date:1/22/2008

New Rochelle, NY, January 22, 2008Can a patient who agrees to participate in a safety study of a gene therapy protocol give truly informed consent and understand the risks involved when the consent forms are highly technical and the physician or institution seeking their consent has a stake in the study and its outcome? The continuing debate over informed consent and the acknowledgement of risk and responsibility in gene therapy trials are the focus of a series of probing and provocative commentaries published in the January 2008 issue (Volume 19, Number 1) of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. The commentaries are available free online.

In the Editorial, James M. Wilson, MD, PhD, Editor-in-Chief and Head of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, at the University of Pennsylvania School of Medicine, in Philadelphia, calls on the gene therapy, regulatory, and research communities to re-explore the issue of informed consent as it relates to the safety of viral vector-based gene transfer therapies and the appropriateness of having physicians and others with an interest in the trials and their outcomes recruit patients and obtain the necessary informed consent.

I encourage the professional gene therapy societies and various related foundations to work together in the new year to undertake a critical review of the conduct of our clinical trials...it behooves us to get ahead of this issue and put in place more effective ways to assure that research subjects who courageously give of themselves can do so with a full and unbiased understanding of the risks and benefits of their participation, writes Dr. Wilson.

This issue of the Journal also includes five stimulating commentaries that discuss the key controversies related to patient recruitment and trial management. They explore the question of whether patients are able to comprehend the lengthy and often highly technical study descriptions and consent forms to the extent needed to make an informed decision about enrolling in a trial. The authors also present suggestions and innovative strategies for improving the recruitment and informed consent process.

Dr. Arthur Caplan, Professor of Bioethics, Chair of the Department of Medical Ethics, and Director of the Center for Bioethics at the University of Pennsylvania, authored a commentary entitled, If It Is Broken Shouldnt it Be Fixed? Informed Consent and Initial Clinical Trials of Gene Therapy. Another, entitled, Case of Leukaemia Associated with X-Linked Severe Combined Immunodeficiency Gene Therapy Trial in London, was prepared by the Board of the European Society of Gene and Cell Therapy, Executive Committee of the Clinigene Network of Excellence, and Executive of the Consort Integrated Project. Dr. Jeffrey Kahn, Director and Professor, Center for Bioethics, at the University of Minnesota Medical School, presents his perspectives in, Informed Consent in Human Gene Transfer Clinical Trials. Also contributing a commentary is Dr. Tomas Jose Silber, Chair of the Institutional Review Board and Director of the Office of Ethics at Childrens National Medical Center, in Washington, D.C. It is entitled, Human Gene Therapy, Consent, and the Realities of Clinical Research: Is It Time for a Research Subject Advocate? Ms. Suzanne Pattee, Vice President of Regulatory and Patient Affairs for the Cystic Fibrosis Foundation authored, Protections for Participants in Gene Therapy Trials: A Patients Perspective.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Related medicine news :

1. Health Insurance Industry Contributions to Politicians Block Regulation, Affordability in Health Care Debate, Says FTCR
2. Cincinnati Adoption Agency Invited to Participate in Values Voter Presidential Debate
3. Docs Debate Drugs vs. Surgery for Angina
4. Doctors Debate Drugs vs. Surgery for Angina
5. New study likely to fuel debate over annual physical exams
6. Post-Debate Statement From AARP Spokesperson Drew Nannis
7. Study fuels debate over whether exercise and body size influence ovarian cancer risk
8. Post-Debate Statement from AARP Board Member Joyce Payne
9. Long Term Care Leader Applauds Clinton for Bringing Critical Issue of Senior Care into the Presidential Debate
10. Mayo Clinic Proceedings provides forum for debate about capital punishment
11. Engaging 2008 Debate, Key Long Term Care Advocacy Groups Offer New Plan to Strengthen Nations Long Term and Post-Acute Care Delivery System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
Breaking Medicine Technology: